Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study

Lung Cancer

Volumn 70, Issue 2, 2010, Pages 180-187

  Reck, M ^a   Frickhofen, Norbert ^b   Cedres, Susana ^c   Gatzemeier, Ulrich ^a   Heigener, David ^a   Fuhr, Heinz Georg ^b   Thall, Aron ^d   Lanzalone, Silvana ^d   Stephenson, Patricia ^e   Ruiz Garcia, Ana ^d   Chao, Richard ^d   Felip, Enriqueta ^c  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b HSK   (Germany)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d PFIZER INC   (United States)

^e Pfizer Italia Srl ^*

Author keywords

Cisplatin; Gemcitabine; Non small cell lung cancer; Sunitinib

Indexed keywords

CISPLATIN; GEMCITABINE; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BODY WEIGHT; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; CYSTITIS; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEARING IMPAIRMENT; HEART ATRIUM THROMBOSIS; HICCUP; HUMAN; INTESTINE OBSTRUCTION; LEG THROMBOSIS; LEUKOPENIA; LIMB PAIN; LIVER METABOLISM; LUNG EMBOLISM; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIODONTAL ABSCESS; PERITONEUM METASTASIS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VERTIGO; VOMITING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PYRROLES;

EID: 77955700137     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.01.016     Document Type: Article

References (29)

1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
2. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21(16):3016-3024.
3. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005, 23(13):2926-2936.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: NSCLC v.2.2008. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
5. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
6. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsch V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27(8):1227-1234.
7. Pirker R., Pereira J.R, Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trail. Lancet 2009, 373(9674):1525-1531.
8. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2(5):471-478.
9. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1):327-337.
10. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003, 20(8):757-766.
11. O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101(9):3597-3605.
12. Shikada Y., Yonemitsu Y., Koga T., Onimaru M., Nakano T., Okano S., et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 2005, 65(16):7241-7248.
13. Yuan A., Yu C.J., Kuo S.H., Chen W.J., Lin F.Y., Luh K.T., et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001, 19(2):432-441.
14. Hasumi Y., Klosowska-Wardega A., Furuhashi M., Ostman A., Heldin C.H., Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 2007, 121(12):2606-2614.
15. Socinski M.A., Novello S., Brahmer J.R., Rosell R., Sanchez J.M., Belani C.P., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(4):650-656.
16. Brahmer J.R., Govindan R., Novello S., Rosell R., Belani C.P., Atkins J.N., et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. J Clin Oncol 2007, 25(18S). [abstract 7542].
17. Christensen J.G., Hall C., Hollister BA Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research 2008, [abstract 1433].
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92(3):205-216.
19. McCort-Tipton M.M., Brus T Validation of a method for the determination of gemcitabine and its metabolite dFdU in human plasma by HPLC with MS/MS detection 2005, Covance Laboratories, Inc., Madison, WI, USA, [Covance Study No. 2100-765].
20. Breeze M Validation of a method for the determination of platinum from cisplatin in human plasma ultrafiltrate using ICP/MS 2006, Covance Laboratories, Inc., Madison, WI, USA, [Covance Study No. 2100-741].
21. Johnson A. Validation report: the measurement of SU011248, SU012662 and SU012487 in EDTA human plasma 2002, BAS Analytics, West Lafayette, IN, USA, [BAS Analytics Project No. 1000-0499].
22. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., Comley M., Whitehouse R.M., Talbot D.C., et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 1997, 75(4):477-481.
23. Crinò L., Scagliotti G., Marangolo M., Figoli F., Clerici M., De Marinis F., et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997, 15(1):297-303.
24. Cardenal F., Lopez-Cabrerizo M.P., Anton A., Alberola V., Massuti B., Carrato A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999, 17(1):12-18.
25. Gaafar R.M., Hamza R., Khaled H.M., Elserafi M., Mansour O., Karim N.A., et al. Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: National Cancer Institute Cairo experience. J Egypt Natl Canc Inst 2004, 16(1):1-7.
26. Kroep J.R., Peters G.J., van Moorsel C.J., Catik A., Vermorken J.B., Pinedo H.M., et al. Gemcitabine-cisplatin: a schedule finding study. Ann Oncol 1999, 10(12):1503-1510.
27. Sandler A.B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000, 18(1):122-130.
28. Piguet D., Chapuis B. Recombinant human granulocyte-macrophage colony-stimulating factor in acquired or chemotherapy-induced neutropenia. An open clinical trial. Acta Oncol 1994, 33(6):639-643.
29. Mayordomo J.I., Rivera F., Díaz-Puente M.T., Lianes P., Colomer R., López-Brea M., et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995, 87(11):803-808.